Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study
Abstract Background Previous studies have suggested an association between the use of direct‐acting antiviral agents (DAAs) for treating hepatitis C virus (HCV) infection and the resulting decrease in the incidence of hepatocellular carcinoma (HCC); however, it is unclear whether DAAs prevent the re...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2061 |
| _version_ | 1797236910452637696 |
|---|---|
| author | Masahito Nakano Hironori Koga Tatsuya Ide Ryoko Kuromatsu Satoru Hashimoto Hiroshi Yatsuhashi Masataka Seike Nobito Higuchi Makoto Nakamuta Satoshi Shakado Shotaro Sakisaka Satoshi Miuma Kazuhiko Nakao Yoko Yoshimaru Yutaka Sasaki Satoshi Oeda Yuichiro Eguchi Yuichi Honma Masaru Harada Kenji Nagata Seiichi Mawatari Akio Ido Tatsuji Maeshiro Shuichi Matsumoto Yuko Takami Tetsuo Sohda Takuji Torimura |
| author_facet | Masahito Nakano Hironori Koga Tatsuya Ide Ryoko Kuromatsu Satoru Hashimoto Hiroshi Yatsuhashi Masataka Seike Nobito Higuchi Makoto Nakamuta Satoshi Shakado Shotaro Sakisaka Satoshi Miuma Kazuhiko Nakao Yoko Yoshimaru Yutaka Sasaki Satoshi Oeda Yuichiro Eguchi Yuichi Honma Masaru Harada Kenji Nagata Seiichi Mawatari Akio Ido Tatsuji Maeshiro Shuichi Matsumoto Yuko Takami Tetsuo Sohda Takuji Torimura |
| author_sort | Masahito Nakano |
| collection | DOAJ |
| description | Abstract Background Previous studies have suggested an association between the use of direct‐acting antiviral agents (DAAs) for treating hepatitis C virus (HCV) infection and the resulting decrease in the incidence of hepatocellular carcinoma (HCC); however, it is unclear whether DAAs prevent the recurrence of HCC after curative treatment for HCC. This study aimed to prospectively investigate HCC recurrence and its predictors after curative treatment for HCC. Methods A total of 3012 patients with chronic HCV infection, with or without cirrhosis, who were treated with DAAs were enrolled between January 1, 2015 and January 31, 2017 as per the institutional review board approved study protocol at 15 institutions, including 10 university hospitals and five high‐volume centers in the Kyusyu area of Japan. Of the 3012 patients, 459 patients who had HCC but were cured with surgery or ablation therapy (curative treatment) before the use of DAAs were included in the analysis. Results During a mean follow‐up period of 29.4 months, 217 (47.2%) patients developed HCC recurrence. The median time to recurrence was 34.0 months, and the 1‐, 2‐, and 3‐year cumulative HCC recurrence rates were 27.1%, 43.4%, and 50.8%, respectively. The risk factors for HCC recurrence were the α‐fetoprotein (AFP) level before DAA therapy (P = 0.0047) and the number of curative treatments for HCC before DAA therapy (P < 0.0001). Conclusions A high AFP level and multiple occurrences of HCC before DAA therapy are associated with a high risk for HCC recurrence after curative treatment. Follow‐up after DAA therapy should include special attention to the abovementioned risk factors. |
| first_indexed | 2024-04-24T17:11:21Z |
| format | Article |
| id | doaj.art-1e69a258c4b74eb6a2d490773bf0ca2a |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-24T17:11:21Z |
| publishDate | 2019-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-1e69a258c4b74eb6a2d490773bf0ca2a2024-03-28T10:30:36ZengWileyCancer Medicine2045-76342019-05-01852646265310.1002/cam4.2061Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort studyMasahito Nakano0Hironori Koga1Tatsuya Ide2Ryoko Kuromatsu3Satoru Hashimoto4Hiroshi Yatsuhashi5Masataka Seike6Nobito Higuchi7Makoto Nakamuta8Satoshi Shakado9Shotaro Sakisaka10Satoshi Miuma11Kazuhiko Nakao12Yoko Yoshimaru13Yutaka Sasaki14Satoshi Oeda15Yuichiro Eguchi16Yuichi Honma17Masaru Harada18Kenji Nagata19Seiichi Mawatari20Akio Ido21Tatsuji Maeshiro22Shuichi Matsumoto23Yuko Takami24Tetsuo Sohda25Takuji Torimura26Division of Gastroenterology, Department of Medicine Kurume University School of Medicine Fukuoka JapanDivision of Gastroenterology, Department of Medicine Kurume University School of Medicine Fukuoka JapanDivision of Gastroenterology, Department of Medicine Kurume University School of Medicine Fukuoka JapanDivision of Gastroenterology, Department of Medicine Kurume University School of Medicine Fukuoka JapanClinical Research Center National Hospital Organization Nagasaki Medical Center Nagasaki JapanClinical Research Center National Hospital Organization Nagasaki Medical Center Nagasaki JapanDepartment of Gastroenterology, Faculty of Medicine Oita University Oita JapanDivision of Gastroenterology National Kyusyu Medical Center Hospital Fukuoka JapanDivision of Gastroenterology National Kyusyu Medical Center Hospital Fukuoka JapanDepartment of Gastroenterology and Medicine Fukuoka University Faculty of Medicine Fukuoka JapanDepartment of Gastroenterology and Medicine Fukuoka University Faculty of Medicine Fukuoka JapanDepartment of Gastroenterology and Hepatology Nagasaki University Hospital Nagasaki JapanDepartment of Gastroenterology and Hepatology Nagasaki University Hospital Nagasaki JapanDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences Kumamoto University Kumamoto JapanDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences Kumamoto University Kumamoto JapanLiver Center Saga University Hospital Saga JapanLiver Center Saga University Hospital Saga JapanThird Department of Internal Medicine University of Occupational and Environmental Health Kitakyushu JapanThird Department of Internal Medicine University of Occupational and Environmental Health Kitakyushu JapanDepartment of Liver Disease University of Miyazaki Hospital Miyazaki JapanDigestive and Lifestyle Diseases Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima JapanDigestive and Lifestyle Diseases Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima JapanFirst Department of Internal Medicine, Faculty of Medicine University of the Ryukyus Okinawa JapanFukuoka Tokushukai Medical Center Fukuoka JapanDepartment of Hepato‐Biliary‐Pancreatic Surgery and Clinical Research Institute National Kyushu Medical Center Hospital Fukuoka JapanHepatology Division Japanese Red Cross Fukuoka Hospital Fukuoka JapanDivision of Gastroenterology, Department of Medicine Kurume University School of Medicine Fukuoka JapanAbstract Background Previous studies have suggested an association between the use of direct‐acting antiviral agents (DAAs) for treating hepatitis C virus (HCV) infection and the resulting decrease in the incidence of hepatocellular carcinoma (HCC); however, it is unclear whether DAAs prevent the recurrence of HCC after curative treatment for HCC. This study aimed to prospectively investigate HCC recurrence and its predictors after curative treatment for HCC. Methods A total of 3012 patients with chronic HCV infection, with or without cirrhosis, who were treated with DAAs were enrolled between January 1, 2015 and January 31, 2017 as per the institutional review board approved study protocol at 15 institutions, including 10 university hospitals and five high‐volume centers in the Kyusyu area of Japan. Of the 3012 patients, 459 patients who had HCC but were cured with surgery or ablation therapy (curative treatment) before the use of DAAs were included in the analysis. Results During a mean follow‐up period of 29.4 months, 217 (47.2%) patients developed HCC recurrence. The median time to recurrence was 34.0 months, and the 1‐, 2‐, and 3‐year cumulative HCC recurrence rates were 27.1%, 43.4%, and 50.8%, respectively. The risk factors for HCC recurrence were the α‐fetoprotein (AFP) level before DAA therapy (P = 0.0047) and the number of curative treatments for HCC before DAA therapy (P < 0.0001). Conclusions A high AFP level and multiple occurrences of HCC before DAA therapy are associated with a high risk for HCC recurrence after curative treatment. Follow‐up after DAA therapy should include special attention to the abovementioned risk factors.https://doi.org/10.1002/cam4.2061DAAHCVhepatocarcinogenesisliver cancerSVR |
| spellingShingle | Masahito Nakano Hironori Koga Tatsuya Ide Ryoko Kuromatsu Satoru Hashimoto Hiroshi Yatsuhashi Masataka Seike Nobito Higuchi Makoto Nakamuta Satoshi Shakado Shotaro Sakisaka Satoshi Miuma Kazuhiko Nakao Yoko Yoshimaru Yutaka Sasaki Satoshi Oeda Yuichiro Eguchi Yuichi Honma Masaru Harada Kenji Nagata Seiichi Mawatari Akio Ido Tatsuji Maeshiro Shuichi Matsumoto Yuko Takami Tetsuo Sohda Takuji Torimura Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study Cancer Medicine DAA HCV hepatocarcinogenesis liver cancer SVR |
| title | Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study |
| title_full | Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study |
| title_fullStr | Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study |
| title_full_unstemmed | Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study |
| title_short | Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study |
| title_sort | predictors of hepatocellular carcinoma recurrence associated with the use of direct acting antiviral agent therapy for hepatitis c virus after curative treatment a prospective multicenter cohort study |
| topic | DAA HCV hepatocarcinogenesis liver cancer SVR |
| url | https://doi.org/10.1002/cam4.2061 |
| work_keys_str_mv | AT masahitonakano predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT hironorikoga predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT tatsuyaide predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT ryokokuromatsu predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT satoruhashimoto predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT hiroshiyatsuhashi predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT masatakaseike predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT nobitohiguchi predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT makotonakamuta predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT satoshishakado predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT shotarosakisaka predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT satoshimiuma predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT kazuhikonakao predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT yokoyoshimaru predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT yutakasasaki predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT satoshioeda predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT yuichiroeguchi predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT yuichihonma predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT masaruharada predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT kenjinagata predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT seiichimawatari predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT akioido predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT tatsujimaeshiro predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT shuichimatsumoto predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT yukotakami predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT tetsuosohda predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy AT takujitorimura predictorsofhepatocellularcarcinomarecurrenceassociatedwiththeuseofdirectactingantiviralagenttherapyforhepatitiscvirusaftercurativetreatmentaprospectivemulticentercohortstudy |